MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.earlhumdev.2017.09.016

Медицинская библиотека · Early human development · 2017

Effects of the early administration of sivelestat sodium on bronchopulmonary dysplasia in infants: A retrospective cohort study.

Ogawa Ryo, Mori Rintaro, Iida Koichi, Uchida Yumiko, Oshiro Makoto, Kageyama Misao, Kato Yuichi, Tanaka Taihei, Nakata Yusei, Nishimura Yutaka, Hokuto Isamu, Bonno Motoki, Matsumoto Naoko, Ito Masato, Takahashi Noriko, Namba Fumihiko

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Chorioamnionitis, or infiltration of the chorioamnion by neutrophils, is a risk factor associated with the development of bronchopulmonary dysplasia. Increased neutrophil elastase levels are observed in the tracheal aspirates of these patients.

AIMS: To examine the effects of early administration of the selective neutrophil elastase inhibitor sivelestat, which is used to treat acute lung injury in adults, on bronchopulmonary dysplasia in extremely premature infants.

STUDY

DESIGN

Retrospective cohort study.

SUBJECTS: This study included extremely low-birth-weight infants born at a gestational age<28weeks. Patients were divided into groups based on the receipt of sivelestat.

OUTCOME MEASURES: The primary outcome was the rate of bronchopulmonary dysplasia-free survival at a postmenstrual age of 36weeks, and the secondary outcomes included various clinically significant factors of neonatal mortality and morbidity and adverse events.

RESULTS

Of the 1031 included neonates, 124 (12.0%) were treated with sivelestat. Significant differences between the groups were noted for gestational age, delivery method, fetal number, the frequency of chorioamnionitis, immunoglobulin M levels, and WBC counts. No differences were identified concerning the bronchopulmonary dysplasia-free survival rate at a postmenstrual age of 36weeks (adjusted odds ratio for sivelestat to control, 0.83; 95% confidence interval=0.53-1.30). Secondary outcomes did not significantly differ between the groups.

CONCLUSIONS

In extremely premature infants, early sivelestat use was not associated with an improved rate of survival without bronchopulmonary dysplasia at a postmenstrual age of 36weeks.

Для цитирования: Ogawa Ryo, Mori Rintaro, Iida Koichi, Uchida Yumiko, Oshiro Makoto, Kageyama Misao, Kato Yuichi, Tanaka Taihei, Nakata Yusei, Nishimura Yutaka, Hokuto Isamu, Bonno Motoki, Matsumoto Naoko, Ito Masato, Takahashi Noriko, Namba Fumihiko. Effects of the early administration of sivelestat sodium on bronchopulmonary dysplasia in infants: A retrospective cohort study.. Early human development. 2017. DOI: 10.1016/j.earlhumdev.2017.09.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.